Global Genetic Modification Therapies Market

Genetic Modification Therapies Comprehensive Study by Type (Gene Therapies, Genetically Modified Cell Therapies, RNA Therapies, Gene Editing), Application (Hospitals, Diagnostics and Testing Laboratories, Academic and Research Organizations, Others) Players and Region - Global Market Outlook to 2029

Genetic Modification Therapies Market by XX Submarkets | Forecast Years 2024-2029  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Industry Background:
Genetic modification therapies are advanced therapies that have the unprecedented ability to offer a one-time cure for severe, debilitating diseases that previously untreatable. Genetic modification therapies market expected to grow in the future due to the rising number of chronic patients and technology advancements for new medicine. Several large and small companies are engaged in clinical trials will boost the market in the forecasted period.

AttributesDetails
Study Period2019-2029
Base Year2023
UnitValue (USD Million)
Key Companies ProfiledCasebia Therapeutics (United States), Acer Therapeutics Inc. (United States), 4D Molecular Therapeutics (United States), Abeona Therapeutics (United States), Editas Medicine (United States), GE Healthcare (United States), Allergan Plc (Ireland), Fate Therapeutics (United States) and Marcala Biotech (Canada)


This growth is primarily driven by High Investment for R&D Activities Pertaining to Genetic Modification Therapies and Increase in the Prevalence of Cancer.

Globally, a noticeable market trend is evident Several Large and Small Companies are Engaged in Clinical Trials Major Players, such as Casebia Therapeutics (United States), Acer Therapeutics Inc. (United States), 4D Molecular Therapeutics (United States), Abeona Therapeutics (United States), Editas Medicine (United States), GE Healthcare (United States), Allergan Plc (Ireland), Fate Therapeutics (United States) and Marcala Biotech (Canada), etc have either set up their manufacturing facilities or are planning to start new provision in the dominated region in the upcoming years.

Key Developments in the Market:
In Oct. , 2019 CRISPR Therapeutics and Bayer today announced proposed plans whereby Casebia Therapeutics, a joint venture between CRISPR Therapeutics and Bayer, would operate under the direct management of CRISPR Therapeutics. Upon closing of the transaction, Casebia Therapeutics would focus on the development of its lead programs in hemophilia, ophthalmology and autoimmune diseases, with Bayer having opt-in rights for two products at IND submission.
In July 2023 Hitachi, Ltd. announced that it has entered a strategic framework collaboration agreement with the world-renowned medical research institution, Brigham and Women's Hospital (BWH), a founding member of the Mass General Brigham healthcare system and a teaching affiliate of the Harvard Medical School,*1 on 29 June.

Influencing Trend:
Several Large and Small Companies are Engaged in Clinical Trials

Market Growth Drivers:
High Investment for R&D Activities Pertaining to Genetic Modification Therapies and Increase in the Prevalence of Cancer

Challenges:
Lack of Awareness about genetic modification therapies in Developing Regions

Restraints:
Government Regulatory Policies and Approval Process

Opportunities:
Growth in the Demand in Developing Countries and Rising Demand for Innovative Therapies in Emerging Economy

AMA Research follows a focused and realistic research framework that provides the ability to study the crucial market dynamics in several regions across the world. Moreover, an in-depth assessment is mostly conducted by our analysts on geographical regions to provide clients and businesses the opportunity to dominate in niche markets and expand in emerging markets across the globe. This market research study also showcases the spontaneously changing Players landscape impacting the growth of the market. Furthermore, our market researchers extensively analyze the products and services offered by multiple players competing to increase their market share and presence.

Customization in the Report
AMA Research features not only specific market forecasts but also includes significant value-added commentary on:
- Market Trends
- Technological Trends and Innovations
- Market Maturity Indicators
- Growth Drivers and Constraints in Genetic Modification Therapies Market
- Analysis about New Entrants in Genetic Modification Therapies Market & Entry/Exit Barriers
- To Seize Powerful Market Opportunities
- Identify Key Business Segments, Market Proposition & Gap Analysis
- An Unbiased Perspective towards Market Performance & Indicators

Against this Challenging Backdrop, Genetic Modification Therapies Study Sheds Light on
— The Genetic Modification Therapies Market status quo and key characteristics. To end this, Analysts at AMA organize and took surveys of the Genetic Modification Therapies industry Players. The resultant snapshot serves as a basis for understanding why and how the industry can be expected to change.
— Where Genetic Modification Therapies industry is heading and what are the top priorities. Insights are drawn from financial analysis, surveys, and interviews with key executives and industry experts.
— How every company in this diverse set of Players can best navigate the emerging competition landscape and follow a strategy that helps them position to hold the value they currently claim or capture the new addressable opportunity.

Report Objectives / Segmentation Covered

By Type
  • Gene Therapies
  • Genetically Modified Cell Therapies
  • RNA Therapies
  • Gene Editing
By Application
  • Hospitals
  • Diagnostics and Testing Laboratories
  • Academic and Research Organizations
  • Others
By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. High Investment for R&D Activities Pertaining to Genetic Modification Therapies
      • 3.2.2. Increase in the Prevalence of Cancer
    • 3.3. Market Challenges
      • 3.3.1. Lack of Awareness about genetic modification therapies in Developing Regions
    • 3.4. Market Trends
      • 3.4.1. Several Large and Small Companies are Engaged in Clinical Trials
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Genetic Modification Therapies, by Type, Application and Region (value and price ) (2018-2023)
    • 5.1. Introduction
    • 5.2. Global Genetic Modification Therapies (Value)
      • 5.2.1. Global Genetic Modification Therapies by: Type (Value)
        • 5.2.1.1. Gene Therapies
        • 5.2.1.2. Genetically Modified Cell Therapies
        • 5.2.1.3. RNA Therapies
        • 5.2.1.4. Gene Editing
      • 5.2.2. Global Genetic Modification Therapies by: Application (Value)
        • 5.2.2.1. Hospitals
        • 5.2.2.2. Diagnostics and Testing Laboratories
        • 5.2.2.3. Academic and Research Organizations
        • 5.2.2.4. Others
      • 5.2.3. Global Genetic Modification Therapies Region
        • 5.2.3.1. South America
          • 5.2.3.1.1. Brazil
          • 5.2.3.1.2. Argentina
          • 5.2.3.1.3. Rest of South America
        • 5.2.3.2. Asia Pacific
          • 5.2.3.2.1. China
          • 5.2.3.2.2. Japan
          • 5.2.3.2.3. India
          • 5.2.3.2.4. South Korea
          • 5.2.3.2.5. Taiwan
          • 5.2.3.2.6. Australia
          • 5.2.3.2.7. Rest of Asia-Pacific
        • 5.2.3.3. Europe
          • 5.2.3.3.1. Germany
          • 5.2.3.3.2. France
          • 5.2.3.3.3. Italy
          • 5.2.3.3.4. United Kingdom
          • 5.2.3.3.5. Netherlands
          • 5.2.3.3.6. Rest of Europe
        • 5.2.3.4. MEA
          • 5.2.3.4.1. Middle East
          • 5.2.3.4.2. Africa
        • 5.2.3.5. North America
          • 5.2.3.5.1. United States
          • 5.2.3.5.2. Canada
          • 5.2.3.5.3. Mexico
    • 5.3. Global Genetic Modification Therapies (Price)
      • 5.3.1. Global Genetic Modification Therapies by: Type (Price)
  • 6. Genetic Modification Therapies: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2023)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Casebia Therapeutics (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Acer Therapeutics Inc. (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. 4D Molecular Therapeutics (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Abeona Therapeutics (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Editas Medicine (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. GE Healthcare (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Allergan Plc (Ireland)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Fate Therapeutics (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Marcala Biotech (Canada)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
  • 7. Global Genetic Modification Therapies Sale, by Type, Application and Region (value and price ) (2024-2029)
    • 7.1. Introduction
    • 7.2. Global Genetic Modification Therapies (Value)
      • 7.2.1. Global Genetic Modification Therapies by: Type (Value)
        • 7.2.1.1. Gene Therapies
        • 7.2.1.2. Genetically Modified Cell Therapies
        • 7.2.1.3. RNA Therapies
        • 7.2.1.4. Gene Editing
      • 7.2.2. Global Genetic Modification Therapies by: Application (Value)
        • 7.2.2.1. Hospitals
        • 7.2.2.2. Diagnostics and Testing Laboratories
        • 7.2.2.3. Academic and Research Organizations
        • 7.2.2.4. Others
      • 7.2.3. Global Genetic Modification Therapies Region
        • 7.2.3.1. South America
          • 7.2.3.1.1. Brazil
          • 7.2.3.1.2. Argentina
          • 7.2.3.1.3. Rest of South America
        • 7.2.3.2. Asia Pacific
          • 7.2.3.2.1. China
          • 7.2.3.2.2. Japan
          • 7.2.3.2.3. India
          • 7.2.3.2.4. South Korea
          • 7.2.3.2.5. Taiwan
          • 7.2.3.2.6. Australia
          • 7.2.3.2.7. Rest of Asia-Pacific
        • 7.2.3.3. Europe
          • 7.2.3.3.1. Germany
          • 7.2.3.3.2. France
          • 7.2.3.3.3. Italy
          • 7.2.3.3.4. United Kingdom
          • 7.2.3.3.5. Netherlands
          • 7.2.3.3.6. Rest of Europe
        • 7.2.3.4. MEA
          • 7.2.3.4.1. Middle East
          • 7.2.3.4.2. Africa
        • 7.2.3.5. North America
          • 7.2.3.5.1. United States
          • 7.2.3.5.2. Canada
          • 7.2.3.5.3. Mexico
    • 7.3. Global Genetic Modification Therapies (Price)
      • 7.3.1. Global Genetic Modification Therapies by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Genetic Modification Therapies: by Type(USD Million)
  • Table 2. Genetic Modification Therapies Gene Therapies , by Region USD Million (2018-2023)
  • Table 3. Genetic Modification Therapies Genetically Modified Cell Therapies , by Region USD Million (2018-2023)
  • Table 4. Genetic Modification Therapies RNA Therapies , by Region USD Million (2018-2023)
  • Table 5. Genetic Modification Therapies Gene Editing , by Region USD Million (2018-2023)
  • Table 6. Genetic Modification Therapies: by Application(USD Million)
  • Table 7. Genetic Modification Therapies Hospitals , by Region USD Million (2018-2023)
  • Table 8. Genetic Modification Therapies Diagnostics and Testing Laboratories , by Region USD Million (2018-2023)
  • Table 9. Genetic Modification Therapies Academic and Research Organizations , by Region USD Million (2018-2023)
  • Table 10. Genetic Modification Therapies Others , by Region USD Million (2018-2023)
  • Table 11. South America Genetic Modification Therapies, by Country USD Million (2018-2023)
  • Table 12. South America Genetic Modification Therapies, by Type USD Million (2018-2023)
  • Table 13. South America Genetic Modification Therapies, by Application USD Million (2018-2023)
  • Table 14. Brazil Genetic Modification Therapies, by Type USD Million (2018-2023)
  • Table 15. Brazil Genetic Modification Therapies, by Application USD Million (2018-2023)
  • Table 16. Argentina Genetic Modification Therapies, by Type USD Million (2018-2023)
  • Table 17. Argentina Genetic Modification Therapies, by Application USD Million (2018-2023)
  • Table 18. Rest of South America Genetic Modification Therapies, by Type USD Million (2018-2023)
  • Table 19. Rest of South America Genetic Modification Therapies, by Application USD Million (2018-2023)
  • Table 20. Asia Pacific Genetic Modification Therapies, by Country USD Million (2018-2023)
  • Table 21. Asia Pacific Genetic Modification Therapies, by Type USD Million (2018-2023)
  • Table 22. Asia Pacific Genetic Modification Therapies, by Application USD Million (2018-2023)
  • Table 23. China Genetic Modification Therapies, by Type USD Million (2018-2023)
  • Table 24. China Genetic Modification Therapies, by Application USD Million (2018-2023)
  • Table 25. Japan Genetic Modification Therapies, by Type USD Million (2018-2023)
  • Table 26. Japan Genetic Modification Therapies, by Application USD Million (2018-2023)
  • Table 27. India Genetic Modification Therapies, by Type USD Million (2018-2023)
  • Table 28. India Genetic Modification Therapies, by Application USD Million (2018-2023)
  • Table 29. South Korea Genetic Modification Therapies, by Type USD Million (2018-2023)
  • Table 30. South Korea Genetic Modification Therapies, by Application USD Million (2018-2023)
  • Table 31. Taiwan Genetic Modification Therapies, by Type USD Million (2018-2023)
  • Table 32. Taiwan Genetic Modification Therapies, by Application USD Million (2018-2023)
  • Table 33. Australia Genetic Modification Therapies, by Type USD Million (2018-2023)
  • Table 34. Australia Genetic Modification Therapies, by Application USD Million (2018-2023)
  • Table 35. Rest of Asia-Pacific Genetic Modification Therapies, by Type USD Million (2018-2023)
  • Table 36. Rest of Asia-Pacific Genetic Modification Therapies, by Application USD Million (2018-2023)
  • Table 37. Europe Genetic Modification Therapies, by Country USD Million (2018-2023)
  • Table 38. Europe Genetic Modification Therapies, by Type USD Million (2018-2023)
  • Table 39. Europe Genetic Modification Therapies, by Application USD Million (2018-2023)
  • Table 40. Germany Genetic Modification Therapies, by Type USD Million (2018-2023)
  • Table 41. Germany Genetic Modification Therapies, by Application USD Million (2018-2023)
  • Table 42. France Genetic Modification Therapies, by Type USD Million (2018-2023)
  • Table 43. France Genetic Modification Therapies, by Application USD Million (2018-2023)
  • Table 44. Italy Genetic Modification Therapies, by Type USD Million (2018-2023)
  • Table 45. Italy Genetic Modification Therapies, by Application USD Million (2018-2023)
  • Table 46. United Kingdom Genetic Modification Therapies, by Type USD Million (2018-2023)
  • Table 47. United Kingdom Genetic Modification Therapies, by Application USD Million (2018-2023)
  • Table 48. Netherlands Genetic Modification Therapies, by Type USD Million (2018-2023)
  • Table 49. Netherlands Genetic Modification Therapies, by Application USD Million (2018-2023)
  • Table 50. Rest of Europe Genetic Modification Therapies, by Type USD Million (2018-2023)
  • Table 51. Rest of Europe Genetic Modification Therapies, by Application USD Million (2018-2023)
  • Table 52. MEA Genetic Modification Therapies, by Country USD Million (2018-2023)
  • Table 53. MEA Genetic Modification Therapies, by Type USD Million (2018-2023)
  • Table 54. MEA Genetic Modification Therapies, by Application USD Million (2018-2023)
  • Table 55. Middle East Genetic Modification Therapies, by Type USD Million (2018-2023)
  • Table 56. Middle East Genetic Modification Therapies, by Application USD Million (2018-2023)
  • Table 57. Africa Genetic Modification Therapies, by Type USD Million (2018-2023)
  • Table 58. Africa Genetic Modification Therapies, by Application USD Million (2018-2023)
  • Table 59. North America Genetic Modification Therapies, by Country USD Million (2018-2023)
  • Table 60. North America Genetic Modification Therapies, by Type USD Million (2018-2023)
  • Table 61. North America Genetic Modification Therapies, by Application USD Million (2018-2023)
  • Table 62. United States Genetic Modification Therapies, by Type USD Million (2018-2023)
  • Table 63. United States Genetic Modification Therapies, by Application USD Million (2018-2023)
  • Table 64. Canada Genetic Modification Therapies, by Type USD Million (2018-2023)
  • Table 65. Canada Genetic Modification Therapies, by Application USD Million (2018-2023)
  • Table 66. Mexico Genetic Modification Therapies, by Type USD Million (2018-2023)
  • Table 67. Mexico Genetic Modification Therapies, by Application USD Million (2018-2023)
  • Table 68. Genetic Modification Therapies: by Type(USD/Units)
  • Table 69. Company Basic Information, Sales Area and Its Competitors
  • Table 70. Company Basic Information, Sales Area and Its Competitors
  • Table 71. Company Basic Information, Sales Area and Its Competitors
  • Table 72. Company Basic Information, Sales Area and Its Competitors
  • Table 73. Company Basic Information, Sales Area and Its Competitors
  • Table 74. Company Basic Information, Sales Area and Its Competitors
  • Table 75. Company Basic Information, Sales Area and Its Competitors
  • Table 76. Company Basic Information, Sales Area and Its Competitors
  • Table 77. Company Basic Information, Sales Area and Its Competitors
  • Table 78. Genetic Modification Therapies: by Type(USD Million)
  • Table 79. Genetic Modification Therapies Gene Therapies , by Region USD Million (2024-2029)
  • Table 80. Genetic Modification Therapies Genetically Modified Cell Therapies , by Region USD Million (2024-2029)
  • Table 81. Genetic Modification Therapies RNA Therapies , by Region USD Million (2024-2029)
  • Table 82. Genetic Modification Therapies Gene Editing , by Region USD Million (2024-2029)
  • Table 83. Genetic Modification Therapies: by Application(USD Million)
  • Table 84. Genetic Modification Therapies Hospitals , by Region USD Million (2024-2029)
  • Table 85. Genetic Modification Therapies Diagnostics and Testing Laboratories , by Region USD Million (2024-2029)
  • Table 86. Genetic Modification Therapies Academic and Research Organizations , by Region USD Million (2024-2029)
  • Table 87. Genetic Modification Therapies Others , by Region USD Million (2024-2029)
  • Table 88. South America Genetic Modification Therapies, by Country USD Million (2024-2029)
  • Table 89. South America Genetic Modification Therapies, by Type USD Million (2024-2029)
  • Table 90. South America Genetic Modification Therapies, by Application USD Million (2024-2029)
  • Table 91. Brazil Genetic Modification Therapies, by Type USD Million (2024-2029)
  • Table 92. Brazil Genetic Modification Therapies, by Application USD Million (2024-2029)
  • Table 93. Argentina Genetic Modification Therapies, by Type USD Million (2024-2029)
  • Table 94. Argentina Genetic Modification Therapies, by Application USD Million (2024-2029)
  • Table 95. Rest of South America Genetic Modification Therapies, by Type USD Million (2024-2029)
  • Table 96. Rest of South America Genetic Modification Therapies, by Application USD Million (2024-2029)
  • Table 97. Asia Pacific Genetic Modification Therapies, by Country USD Million (2024-2029)
  • Table 98. Asia Pacific Genetic Modification Therapies, by Type USD Million (2024-2029)
  • Table 99. Asia Pacific Genetic Modification Therapies, by Application USD Million (2024-2029)
  • Table 100. China Genetic Modification Therapies, by Type USD Million (2024-2029)
  • Table 101. China Genetic Modification Therapies, by Application USD Million (2024-2029)
  • Table 102. Japan Genetic Modification Therapies, by Type USD Million (2024-2029)
  • Table 103. Japan Genetic Modification Therapies, by Application USD Million (2024-2029)
  • Table 104. India Genetic Modification Therapies, by Type USD Million (2024-2029)
  • Table 105. India Genetic Modification Therapies, by Application USD Million (2024-2029)
  • Table 106. South Korea Genetic Modification Therapies, by Type USD Million (2024-2029)
  • Table 107. South Korea Genetic Modification Therapies, by Application USD Million (2024-2029)
  • Table 108. Taiwan Genetic Modification Therapies, by Type USD Million (2024-2029)
  • Table 109. Taiwan Genetic Modification Therapies, by Application USD Million (2024-2029)
  • Table 110. Australia Genetic Modification Therapies, by Type USD Million (2024-2029)
  • Table 111. Australia Genetic Modification Therapies, by Application USD Million (2024-2029)
  • Table 112. Rest of Asia-Pacific Genetic Modification Therapies, by Type USD Million (2024-2029)
  • Table 113. Rest of Asia-Pacific Genetic Modification Therapies, by Application USD Million (2024-2029)
  • Table 114. Europe Genetic Modification Therapies, by Country USD Million (2024-2029)
  • Table 115. Europe Genetic Modification Therapies, by Type USD Million (2024-2029)
  • Table 116. Europe Genetic Modification Therapies, by Application USD Million (2024-2029)
  • Table 117. Germany Genetic Modification Therapies, by Type USD Million (2024-2029)
  • Table 118. Germany Genetic Modification Therapies, by Application USD Million (2024-2029)
  • Table 119. France Genetic Modification Therapies, by Type USD Million (2024-2029)
  • Table 120. France Genetic Modification Therapies, by Application USD Million (2024-2029)
  • Table 121. Italy Genetic Modification Therapies, by Type USD Million (2024-2029)
  • Table 122. Italy Genetic Modification Therapies, by Application USD Million (2024-2029)
  • Table 123. United Kingdom Genetic Modification Therapies, by Type USD Million (2024-2029)
  • Table 124. United Kingdom Genetic Modification Therapies, by Application USD Million (2024-2029)
  • Table 125. Netherlands Genetic Modification Therapies, by Type USD Million (2024-2029)
  • Table 126. Netherlands Genetic Modification Therapies, by Application USD Million (2024-2029)
  • Table 127. Rest of Europe Genetic Modification Therapies, by Type USD Million (2024-2029)
  • Table 128. Rest of Europe Genetic Modification Therapies, by Application USD Million (2024-2029)
  • Table 129. MEA Genetic Modification Therapies, by Country USD Million (2024-2029)
  • Table 130. MEA Genetic Modification Therapies, by Type USD Million (2024-2029)
  • Table 131. MEA Genetic Modification Therapies, by Application USD Million (2024-2029)
  • Table 132. Middle East Genetic Modification Therapies, by Type USD Million (2024-2029)
  • Table 133. Middle East Genetic Modification Therapies, by Application USD Million (2024-2029)
  • Table 134. Africa Genetic Modification Therapies, by Type USD Million (2024-2029)
  • Table 135. Africa Genetic Modification Therapies, by Application USD Million (2024-2029)
  • Table 136. North America Genetic Modification Therapies, by Country USD Million (2024-2029)
  • Table 137. North America Genetic Modification Therapies, by Type USD Million (2024-2029)
  • Table 138. North America Genetic Modification Therapies, by Application USD Million (2024-2029)
  • Table 139. United States Genetic Modification Therapies, by Type USD Million (2024-2029)
  • Table 140. United States Genetic Modification Therapies, by Application USD Million (2024-2029)
  • Table 141. Canada Genetic Modification Therapies, by Type USD Million (2024-2029)
  • Table 142. Canada Genetic Modification Therapies, by Application USD Million (2024-2029)
  • Table 143. Mexico Genetic Modification Therapies, by Type USD Million (2024-2029)
  • Table 144. Mexico Genetic Modification Therapies, by Application USD Million (2024-2029)
  • Table 145. Genetic Modification Therapies: by Type(USD/Units)
  • Table 146. Research Programs/Design for This Report
  • Table 147. Key Data Information from Secondary Sources
  • Table 148. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Genetic Modification Therapies: by Type USD Million (2018-2023)
  • Figure 5. Global Genetic Modification Therapies: by Application USD Million (2018-2023)
  • Figure 6. South America Genetic Modification Therapies Share (%), by Country
  • Figure 7. Asia Pacific Genetic Modification Therapies Share (%), by Country
  • Figure 8. Europe Genetic Modification Therapies Share (%), by Country
  • Figure 9. MEA Genetic Modification Therapies Share (%), by Country
  • Figure 10. North America Genetic Modification Therapies Share (%), by Country
  • Figure 11. Global Genetic Modification Therapies: by Type USD/Units (2018-2023)
  • Figure 12. Global Genetic Modification Therapies share by Players 2023 (%)
  • Figure 13. Global Genetic Modification Therapies share by Players (Top 3) 2023(%)
  • Figure 14. Global Genetic Modification Therapies share by Players (Top 5) 2023(%)
  • Figure 15. BCG Matrix for key Companies
  • Figure 16. Casebia Therapeutics (United States) Revenue, Net Income and Gross profit
  • Figure 17. Casebia Therapeutics (United States) Revenue: by Geography 2023
  • Figure 18. Acer Therapeutics Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 19. Acer Therapeutics Inc. (United States) Revenue: by Geography 2023
  • Figure 20. 4D Molecular Therapeutics (United States) Revenue, Net Income and Gross profit
  • Figure 21. 4D Molecular Therapeutics (United States) Revenue: by Geography 2023
  • Figure 22. Abeona Therapeutics (United States) Revenue, Net Income and Gross profit
  • Figure 23. Abeona Therapeutics (United States) Revenue: by Geography 2023
  • Figure 24. Editas Medicine (United States) Revenue, Net Income and Gross profit
  • Figure 25. Editas Medicine (United States) Revenue: by Geography 2023
  • Figure 26. GE Healthcare (United States) Revenue, Net Income and Gross profit
  • Figure 27. GE Healthcare (United States) Revenue: by Geography 2023
  • Figure 28. Allergan Plc (Ireland) Revenue, Net Income and Gross profit
  • Figure 29. Allergan Plc (Ireland) Revenue: by Geography 2023
  • Figure 30. Fate Therapeutics (United States) Revenue, Net Income and Gross profit
  • Figure 31. Fate Therapeutics (United States) Revenue: by Geography 2023
  • Figure 32. Marcala Biotech (Canada) Revenue, Net Income and Gross profit
  • Figure 33. Marcala Biotech (Canada) Revenue: by Geography 2023
  • Figure 34. Global Genetic Modification Therapies: by Type USD Million (2024-2029)
  • Figure 35. Global Genetic Modification Therapies: by Application USD Million (2024-2029)
  • Figure 36. South America Genetic Modification Therapies Share (%), by Country
  • Figure 37. Asia Pacific Genetic Modification Therapies Share (%), by Country
  • Figure 38. Europe Genetic Modification Therapies Share (%), by Country
  • Figure 39. MEA Genetic Modification Therapies Share (%), by Country
  • Figure 40. North America Genetic Modification Therapies Share (%), by Country
  • Figure 41. Global Genetic Modification Therapies: by Type USD/Units (2024-2029)
List of companies from research coverage that are profiled in the study
  • Casebia Therapeutics (United States)
  • Acer Therapeutics Inc. (United States)
  • 4D Molecular Therapeutics (United States)
  • Abeona Therapeutics (United States)
  • Editas Medicine (United States)
  • GE Healthcare (United States)
  • Allergan Plc (Ireland)
  • Fate Therapeutics (United States)
  • Marcala Biotech (Canada)
Additional players considered in the study are as follows:
American Gene Technologies International Inc. (United States) , Krystal Biotech (United States)
Select User Access Type

Key Highlights of Report


Jan 2024 249 Pages 83 Tables Base Year: 2023 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Genetic Modification Therapies Market Quantitative research analysis
Global Genetic Modification Therapies Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

Top performing companies in the Global Genetic Modification Therapies market are Casebia Therapeutics (United States), Acer Therapeutics Inc. (United States), 4D Molecular Therapeutics (United States), Abeona Therapeutics (United States), Editas Medicine (United States), GE Healthcare (United States), Allergan Plc (Ireland), Fate Therapeutics (United States) and Marcala Biotech (Canada), to name a few.
is dominating the Genetic Modification Therapies Market.
"Lack of Awareness about genetic modification therapies in Developing Regions" is seen as one of the major challenges by many Industry Players of Genetic Modification Therapies Market
The Genetic Modification Therapies market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get complete companies available in our research coverage.
The Genetic Modification Therapies market is expected to see a steady growth rate during projected year 2023 to 2029.

Know More About Global Genetic Modification Therapies Market Report?

Have a Query? Click Here

Other Related Reports

Brain Tumor Therapeutics Comprehensive Study by Type (MRI, CT Scan, Tissue Sampling, PET-CT Scan, Cerebral Arteriogram, Lumbar Puncture, Molecular Testing, EEG), Treatment Type (Surgery, Radiation Th...
$ 3650
Retinal Biologics Comprehensive Study by Application (Hospitals, Clinics, Research Organizations, Others), Diagnostic Tests (Amsler grid test, Optical coherence tomography (OCT), Fundus autofluoresce...
$ 3650
Enteric Empty Capsules Comprehensive Study by Type (Gelatin Capsules (Pig Meat Gelatin, Bovine-Derived Gelatin.Bone Meal, and Other Gelatin Sources), Non-Gelatin Capsules (Hydroxypropyl Methylcellulo...
$ 3750
Mouth Ulcer Treatment Drug Comprehensive Study by Route of Administration (Oral, Topical), Drugs Class (Corticosteroid, Analgesic, Antibiotic, Anti-Inflammatory, Others), Distribution Channel (Hospit...
$ 3800
Alopecia Treatment Comprehensive Study by Type (Topical Drugs (Creams, Oils, Gels, Shampoo, Lotions, Foams), Oral Drugs, Injectable Drugs (Platelet-rich Plasma. Injections, Injectable Fillers), Hair ...
$ 3750
Sleep Disorders Comprehensive Study by Type (Mattresses and Pillows, Sleep Laboratories, Medications, Sleep Disorder Devices), Category (Insomnia, Hypersomnia, Sleep apnea, Sleep breathing disorders,...
$ 3750